TIGIT is a coinhibitory receptor that binds to PVR on APCs and tumor
cells in various solid and hematologic tumors.1-3 TIGIT dampens
the immune response by competing with its costimulatory counterpart,
CD226, for binding to PVR.1,2 Preventing PVR-TIGIT
interaction may restore anti-tumor immunity, thereby complementing
PD-L1 inhibition, as shown in preclinical models.1 TIGIT
was identified at Genentech.2,4
Targeting PVR-TIGIT interaction may be one approach3
Targeting TIGIT may enhance Teff function.1
Targeting TIGIT may activate NK cells.5
Targeting TIGIT may counter T reg-mediated immune suppression.6
APC=antigen-presenting cell; IgG1=immunoglobulin
G1; NK=natural killer; PD-1=programmed
cell death protein 1; PD-L1=programmed
cell-death ligand 1; PVR=poliovirus receptor; Teff=effector T cell; Treg=regulatory T cell;
TIGIT=T-cell immunoreceptor with immunoglobulin and immunoreceptor
tyrosine-based inhibitory motif domains.